HUP0304045A3 - Use of ikb-kinase inhibitors for treating of inflammatory and immune diseases and pharmaceutical compositions containing them - Google Patents

Use of ikb-kinase inhibitors for treating of inflammatory and immune diseases and pharmaceutical compositions containing them

Info

Publication number
HUP0304045A3
HUP0304045A3 HU0304045A HUP0304045A HUP0304045A3 HU P0304045 A3 HUP0304045 A3 HU P0304045A3 HU 0304045 A HU0304045 A HU 0304045A HU P0304045 A HUP0304045 A HU P0304045A HU P0304045 A3 HUP0304045 A3 HU P0304045A3
Authority
HU
Hungary
Prior art keywords
ikb
inflammatory
treating
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0304045A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Bristol Myers Squibb Company P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/965,977 external-priority patent/US6960585B2/en
Application filed by Bristol Myers Squibb Company P filed Critical Bristol Myers Squibb Company P
Publication of HUP0304045A2 publication Critical patent/HUP0304045A2/hu
Publication of HUP0304045A3 publication Critical patent/HUP0304045A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HU0304045A 2001-02-01 2002-02-01 Use of ikb-kinase inhibitors for treating of inflammatory and immune diseases and pharmaceutical compositions containing them HUP0304045A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26585301P 2001-02-01 2001-02-01
US09/965,977 US6960585B2 (en) 2000-10-03 2001-09-27 Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
PCT/US2002/003060 WO2002060386A2 (fr) 2001-02-01 2002-02-01 Methodes de traitement de maladies inflammatoires et immunitaires a l'aide d'inhibiteurs d'i$g(k)b kinase (ikk)

Publications (2)

Publication Number Publication Date
HUP0304045A2 HUP0304045A2 (hu) 2004-04-28
HUP0304045A3 true HUP0304045A3 (en) 2005-05-30

Family

ID=26951465

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0304045A HUP0304045A3 (en) 2001-02-01 2002-02-01 Use of ikb-kinase inhibitors for treating of inflammatory and immune diseases and pharmaceutical compositions containing them

Country Status (10)

Country Link
EP (1) EP1363993A4 (fr)
JP (1) JP2004529088A (fr)
AU (1) AU2002247059B2 (fr)
CA (1) CA2436770A1 (fr)
CZ (1) CZ20032287A3 (fr)
HU (1) HUP0304045A3 (fr)
MX (1) MXPA03006817A (fr)
NO (1) NO20033429L (fr)
PL (1) PL364111A1 (fr)
WO (1) WO2002060386A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960585B2 (en) * 2000-10-03 2005-11-01 Bristol-Myers Squibb Company Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
IL155519A0 (en) 2000-10-26 2003-11-23 Tularik Inc Antiinflammation agents
AU2002365611A1 (en) 2001-12-05 2003-06-17 F. Hoffmann - La Roche Ag Inflammation modulators
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
JP2006512313A (ja) 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
PE20060373A1 (es) 2004-06-24 2006-04-29 Smithkline Beecham Corp Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
UA99699C2 (ru) 2005-06-30 2012-09-25 Смитклайн Бичам Корпорейшн Производные индолкарбоксамида и фармацевтическая композиция, которая их содержит
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
CN101304736A (zh) * 2005-09-07 2008-11-12 雪兰诺实验室公司 治疗子宫内膜异位症的ikk抑制剂
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
KR101555384B1 (ko) * 2006-12-13 2015-09-23 아스카 세이야쿠 가부시키가이샤 퀴녹살린 유도체
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
WO2009132050A2 (fr) 2008-04-21 2009-10-29 Otonomy, Inc. Préparations auriculaires de traitement de maladies et états otiques
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
WO2010000903A2 (fr) * 2008-06-30 2010-01-07 Centro De Investigaciones Energéticas, Medioambientales Y Tecnológicas (Ciemat) Composition permettant de moduler l'activité d'ikkalpha, destinée au traitement de maladies associées à l'acantholyse
CN102171204B (zh) 2008-10-02 2014-08-20 旭化成制药株式会社 8位取代异喹啉衍生物及其用途
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
KR20190024983A (ko) 2016-06-29 2019-03-08 오토노미, 인코포레이티드 트리글리세라이드 귀 제제 및 이의 용도
EP3494994A1 (fr) * 2017-12-07 2019-06-12 Universität zu Köln Combinaisons d'inhibiteurs de ripk1 et d'ikk pour la prévention ou le traitement de maladies immunitaires

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160097A (en) * 1977-01-07 1979-07-03 Westwind Pharmaceuticals, Inc. 1-(2-Phenylureylene)imidazoles
US5851812A (en) * 1997-07-01 1998-12-22 Tularik Inc. IKK-β proteins, nucleic acids and methods
US6235740B1 (en) * 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6030834A (en) * 1997-12-30 2000-02-29 Chiron Corporation Human IKK-beta DNA constructs and cells
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
RU2277095C2 (ru) * 2000-03-15 2006-05-27 Санофи-Авентис Дойчланд Гмбх Замещенные бета-карболины
US6960585B2 (en) * 2000-10-03 2005-11-01 Bristol-Myers Squibb Company Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same

Also Published As

Publication number Publication date
CA2436770A1 (fr) 2002-08-08
HUP0304045A2 (hu) 2004-04-28
JP2004529088A (ja) 2004-09-24
NO20033429D0 (no) 2003-07-31
EP1363993A4 (fr) 2008-11-12
WO2002060386A3 (fr) 2002-10-10
AU2002247059B2 (en) 2006-11-16
PL364111A1 (en) 2004-12-13
MXPA03006817A (es) 2003-11-13
WO2002060386A2 (fr) 2002-08-08
EP1363993A2 (fr) 2003-11-26
CZ20032287A3 (cs) 2004-02-18
NO20033429L (no) 2003-09-24

Similar Documents

Publication Publication Date Title
HUP0304045A3 (en) Use of ikb-kinase inhibitors for treating of inflammatory and immune diseases and pharmaceutical compositions containing them
EP1575480A4 (fr) Compositions et methodes de traitement de maladies relatives au systeme immunitaire
EP1578367A4 (fr) Compositions et methodes pour le traitement de maladies liees au systeme immunitaire
EP1572116A4 (fr) Compositions et procedes destines au traitement de maladies de nature immune
EP1576137A4 (fr) Compositions et methodes de traitement de maladies liees au systeme immunitaire
TWI346558B (en) Pharmaceutical composition for chronic treatment of inflammation and use thereof
HUP0401711A3 (en) N-heterocyclic inhibitors of tnf-alpha and pharmaceutical compositions containing them
HUP0201463A3 (en) Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect and their use
EP1443905A4 (fr) Compositions pour therapie genique orale et procedes d'utilisation associes
EP1383743A4 (fr) Doubles inhibiteurs de la pde 7 et de la pde 4
HK1091840A1 (en) Methods and compositions for therapeutic use of rna interference
IL166108A0 (en) Novel compounds pharmaceutical compositions containing same and methods of use for same
HUP0400918A3 (en) Utilization of pyrazoline derivatives in the preparation of pharmaceutical compositions for the prevention and/or treatment of proliferative cell diseases
EP1560593A4 (fr) Nouvelle composition et procedes pour le traitement de maladies auto-immunes
EP1379242A4 (fr) Methode de traitement de cancers et compositions appropriees
HUP0201846A3 (en) Amonobenzophenones as inhibitors of il-1betha and tnf-alpha and pharmaceutical compositions containing them
HUP0200613A2 (en) Compounds and methods for treatment of asthma, allergy and inflammatory disorders, pharmaceutical compositions containing them and their use
HUP0401392A3 (en) Use of composition comprising anti-hla-antibody for treatment of diseases involving prolierative immune response
IL166054A0 (en) Novel compounds pharmaceutical compositions containing same and methods of use for same
EP1691820A4 (fr) Preparation et composition de proteines d'inhibiteur inter-alpha a partir du plasma humain, a usage therapeutique
EP1578373A4 (fr) Nouvelles compositions et methodes pour le traitement de maladies associees au systeme immunitaire
EP1416795A4 (fr) Compositions et procedes pour le traitement de maladies mitochondriales
IL156506A0 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
EP1424897A4 (fr) Compositions et methodes pour le traitement du cancer

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees